These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24820737)

  • 61. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
    Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study.
    García-González MJ; de Mora-Martín M; López-Fernández S; López-Díaz J; Martínez-Sellés M; Romero-García J; Cordero M; Lara-Padrón A; Marrero-Rodríguez F; del Mar García-Saiz M; Aldea-Perona A;
    Cardiovasc Drugs Ther; 2013 Dec; 27(6):573-9. PubMed ID: 23887741
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of outcomes for patients with nonischemic cardiomyopathy taking intravenous inotropes versus those weaned from or never taking inotropes at cardiac resynchronization therapy.
    Adelstein E; Bhattacharya S; Simon MA; Gorcsan J; Saba S
    Am J Cardiol; 2012 Sep; 110(6):857-61. PubMed ID: 22681865
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
    Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
    Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial.
    Böhm M; Link A; Cai D; Nieminen MS; Filippatos GS; Salem R; Cohen Solal A; Huang B; Padley RJ; Kivikko M; Mebazaa A
    Crit Care Med; 2011 May; 39(5):940-4. PubMed ID: 21283007
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.
    Packer M; Colucci W; Fisher L; Massie BM; Teerlink JR; Young J; Padley RJ; Thakkar R; Delgado-Herrera L; Salon J; Garratt C; Huang B; Sarapohja T;
    JACC Heart Fail; 2013 Apr; 1(2):103-11. PubMed ID: 24621834
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmaco-economics of levosimendan in cardiology: a European perspective.
    Nieminen MS; Buerke M; Parissis J; Ben-Gal T; Pollesello P; Kivikko M; Karavidas A; Severino P; Comín-Colet J; Wikström G; Fedele F
    Int J Cardiol; 2015 Nov; 199():337-41. PubMed ID: 26241640
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Haemodynamic effects of levosimendan in advanced but stable chronic heart failure.
    Najjar E; Stålhberg M; Hage C; Ottenblad E; Manouras A; Haugen Löfman I; Lund LH
    ESC Heart Fail; 2018 Jun; 5(3):302-308. PubMed ID: 29469177
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessment of sustained effects of levosimendan on right ventricular systolic functions in patients with advanced heart failure.
    Mansiroglu AK; Oner E; Erturk M; Karakurt H; Somuncu MU; Birant A; Kalkan AK; Ozturk D; Eksik A
    Acta Cardiol; 2016 Aug; 71(4):411-5. PubMed ID: 27594356
    [No Abstract]   [Full Text] [Related]  

  • 70. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials.
    Silvetti S; Belletti A; Fontana A; Pollesello P
    ESC Heart Fail; 2017 Nov; 4(4):595-604. PubMed ID: 28834396
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Scheduled intermittent inotropes for Ambulatory Advanced Heart Failure. The RELEVANT-HF multicentre collaboration.
    Oliva F; Perna E; Marini M; Nassiacos D; Cirò A; Malfatto G; Morandi F; Caico I; Perna G; Meloni S; Vincenzi A; Villani A; Vecchi AL; Minoia C; Verde A; De Maria R;
    Int J Cardiol; 2018 Dec; 272():255-259. PubMed ID: 30131229
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment with inotropes and related prognosis in acute heart failure: contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry.
    Mortara A; Oliva F; Metra M; Carbonieri E; Di Lenarda A; Gorini M; Midi P; Senni M; Urso R; Lucci D; Maggioni AP; Tavazzi L;
    J Heart Lung Transplant; 2014 Oct; 33(10):1056-65. PubMed ID: 25049067
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative Effectiveness and Safety of Milrinone and Levosimendan as Initial Inotrope Therapy in Patients With Acute Heart Failure With Renal Dysfunction.
    Cui X; Wang Z; Dong X; Cheng Z; Zhang L; Mu Y; Huang X; Li Y; Hong Y; Han Y
    J Cardiovasc Pharmacol; 2022 Jun; 79(6):781-790. PubMed ID: 35507915
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes.
    López-Candales AL; Carron C; Schwartz J
    Clin Cardiol; 2004 Jan; 27(1):23-8. PubMed ID: 14743852
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Levosimendan--an inoprotective drug or much ado about nothing?
    Lehmann A; Radke J; Sack FU
    Crit Care Med; 2011 Oct; 39(10):2365-6. PubMed ID: 21926495
    [No Abstract]   [Full Text] [Related]  

  • 76. Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines.
    Allen LA; Fonarow GC; Grau-Sepulveda MV; Hernandez AF; Peterson PN; Partovian C; Li SX; Heidenreich PA; Bhatt DL; Peterson ED; Krumholz HM;
    Circ Heart Fail; 2014 Mar; 7(2):251-60. PubMed ID: 24488983
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period.
    Pölzl G; Allipour Birgani S; Comín-Colet J; Delgado JF; Fedele F; García-Gonzáles MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Vrtovec B; Wikström G; Altenberger J
    ESC Heart Fail; 2019 Feb; 6(1):174-181. PubMed ID: 30378288
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Do levosimendan have an adverse effect on platelet function?
    Kaptan K; Beyan C; Ifran A
    Int J Cardiol; 2010 Oct; 144(3):414-5. PubMed ID: 19327852
    [No Abstract]   [Full Text] [Related]  

  • 79. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
    Dobarro D; Donoso-Trenado V; Solé-González E; Moliner-Abós C; Garcia-Pinilla JM; Lopez-Fernandez S; Ruiz-Bustillo S; Diez-Lopez C; Castrodeza J; Méndez-Fernández AB; Vaqueriza-Cubillo D; Cobo-Marcos M; Tobar J; Sagasti-Aboitiz I; Rodriguez M; Escolar V; Abecia A; Codina P; Gómez-Otero I; Pastor F; Marzoa-Rivas R; González-Babarro E; de Juan-Baguda J; Melendo-Viu M; de Frutos F; Gonzalez-Costello J
    ESC Heart Fail; 2023 Apr; 10(2):1193-1204. PubMed ID: 36655614
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application.
    Bouchez S; Fedele F; Giannakoulas G; Gustafsson F; Harjola VP; Karason K; Kivikko M; von Lewinski D; Oliva F; Papp Z; Parissis J; Pollesello P; Pölzl G; Tschöpe C
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):617-624. PubMed ID: 30402660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.